3 Must-Buy Stocks for June 2025 – Top Analysts Reveal Their Picks

Wall Street's sharpest minds are doubling down on these equities—just as retail investors start panic-selling.

The Contrarian Play: One battered tech stock with 300% upside potential (if the Fed stops playing whack-a-mole with rates).

The Safe Harbor: A dividend aristocrat quietly printing money while crypto bros chase the next memecoin.

The Dark Horse: An AI infrastructure play most analysts missed—until its earnings cratered competitors' share prices.

Remember: These 'top picks' come from the same geniuses who missed every market crash since 2008. Do your own damn research.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

(MSTR) – Strategy is a business intelligence company best known for its large Bitcoin holdings and data analytics software. Yesterday, TD Cowen analyst Lance Vitanza maintained a Buy rating on the stock with a price target of $590 per share. In the last three months, all nine Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 55.54%.

(IRON) – This is a clinical-stage biotech company focused on novel treatments for hematologic diseases, including anemia and blood disorders. Yesterday, H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on the stock with a price target of $118 per share. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 103.8%.

(ELV) – Elevance Health is a U.S.-based healthcare company offering an integrated “whole-health” model. Yesterday,UBS analyst A.J. Rice maintained a Buy rating on the stock with a target price of $555 per share. Interestingly, seven out of the eight Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 30%. 

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page. 

Disclosure